Treatment response of CNS high-grade neuroepithelial tumors with MN1 alteration.
Lorena V BaroniCarlos RugiloFabiana LubienieckiClaudia SamporCandela FreytesLiana NobreJordan R HansfordVajiranee S MalalasekeraMichal ZapotockyAndrew DodgshunOfelia Cruz MartinezAndrés Morales La MadridCinzia LavarinoMariona SuñolStefan RutkowskiUlrich SchullerEric BouffetVijay RamsawamiDaniel AlderetePublished in: Pediatric blood & cancer (2020)
Central nervous system high-grade neuroepithelial tumor with MN1 alteration (CNS HGNET-MN1) is a rare recently described entity. Fourteen CNS HGNET-MN1 patients were identified using genome-wide methylation arrays/RT-PCR across seven institutions. All patients had surgery (gross total resection: 10; subtotal resection: four) as initial management followed by observation alone in three patients, followed by radiotherapy in eight patients (focal: five; craniospinal: two; CyberKnife: one) and systemic chemotherapy in three patients. Seven patients relapsed; five local and two metastatic, despite adjuvant radiotherapy, of which three died. Treatment of CNS HGNET-MN1 remains a major treatment challenge despite aggressive surgical resections and upfront radiotherapy, warranting new approaches to this rare malignancy.
Keyphrases
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- high grade
- early stage
- genome wide
- peritoneal dialysis
- acute myeloid leukemia
- acute lymphoblastic leukemia
- small cell lung cancer
- radiation therapy
- gene expression
- dna methylation
- minimally invasive
- coronary artery disease
- acute coronary syndrome
- room temperature
- locally advanced
- rectal cancer
- multiple myeloma
- drug induced
- high density